{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:25:14Z","timestamp":1791167114060,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":959,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.seizure.2010.10.027","type":"journal-article","created":{"date-parts":[[2010,11,13]],"date-time":"2010-11-13T04:31:59Z","timestamp":1289622719000},"page":"650-655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":227,"title":["Antiepileptic drug therapy the story so far"],"prefix":"10.1016","volume":"19","author":[{"given":"Martin J.","family":"Brodie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2010.10.027_bib0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1192\/bjp.14.67.305","article-title":"Experiments to determine the precise effect of bromide of potassium in epilepsy","author":"Clouston","year":"1868","journal-title":"J Ment Sci"},{"key":"10.1016\/j.seizure.2010.10.027_bib0010","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0883073807302758","article-title":"Pharmacology, efficacy and tolerability of potassium bromide in childhood Epilepsy","volume":"22","author":"Korinthenberg","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2010.10.027_bib0015","first-page":"1907","article-title":"Luminal bei epilepsie","volume":"59","author":"Hauptmann","year":"1912","journal-title":"Munch Med Wochenshr"},{"key":"10.1016\/j.seizure.2010.10.027_bib0020","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.0013-9580.2004.12704.x","article-title":"Phenobarbital for the treatment of epilepsy in the 21st century: a critical review","author":"Kwan","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0025","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1001\/jama.1938.02790380010004","article-title":"Sodium diphenylhydantonate in the treatment of convulsive disorders","volume":"111","author":"Merritt","year":"1938","journal-title":"JAMA"},{"key":"10.1016\/j.seizure.2010.10.027_bib0030","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa0902014","article-title":"Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy","volume":"362","author":"Glauser","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2010.10.027_bib0035","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1528-1167.2006.00585.x","article-title":"ILAE treatment guidelines: evidence-based analysis of antiepileptic drug therapy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"47","author":"Glauser","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0040","first-page":"435","article-title":"Pharmacodynamic properties of dipropylactic acid. 1. Anticonvulsive action","volume":"18","author":"Meunier","year":"1963","journal-title":"Therapie"},{"key":"10.1016\/j.seizure.2010.10.027_bib0045","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1528-1157.1973.tb03965.x","article-title":"Benzodiazepines in the treatment of epilepsy: a review","volume":"14","author":"Browne","year":"1973","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0050","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1528-1157.1965.tb03786.x","article-title":"Treatment of status epilepticus with diazepam (valium)","volume":"6","author":"Gastaut","year":"1965","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0055","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1528-1157.1971.tb04928.x","article-title":"Treatment of status epilepticus with a new benzodiazepine more active than diazepam","volume":"12","author":"Gastaut","year":"1971","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0060","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.nurt.2006.11.002","article-title":"Clobazam","volume":"4","author":"Silva","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.seizure.2010.10.027_bib0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nurt.2006.11.009","article-title":"Discovery of antiepileptic drugs","volume":"4","author":"Smith","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.seizure.2010.10.027_bib0070","series-title":"Encyclopaedia of basic research in epilepsy","first-page":"97","article-title":"Preclinical drug development in epilepsy","author":"Sills","year":"2009"},{"key":"10.1016\/j.seizure.2010.10.027_bib0075","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14728214.12.3.407","article-title":"Emerging drugs for epilepsy","volume":"12","author":"Kwan","year":"2007","journal-title":"Expert Opin Emerging Drugs"},{"key":"10.1016\/j.seizure.2010.10.027_bib0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/14737175.9.1.33","article-title":"Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety: data in partial onset seizures","volume":"9","author":"Beydoun","year":"2009","journal-title":"Expert Rev Neurotherapeutics"},{"key":"10.1016\/j.seizure.2010.10.027_bib0085","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2165\/00003495-200666140-00004","article-title":"Combination therapy in epilepsy. When and what to use","volume":"66","author":"Kwan","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.seizure.2010.10.027_bib0090","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrn1430","article-title":"The neurobiology of antiepileptic drugs","volume":"5","author":"Rogawski","year":"2004","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.seizure.2010.10.027_bib0095","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/j.1528-1167.2009.02160.x","article-title":"Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial","volume":"50","author":"Brodie","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0100","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","article-title":"Rufinamide for generalised seizures associated with Lennox-Gastaut syndrome","volume":"70","author":"Glauser","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2010.10.027_bib0105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.nurt.2006.11.010","article-title":"Molecular targets for antiepileptic drug development","volume":"4","author":"Meldrum","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.seizure.2010.10.027_bib0110","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1684\/j.1950-6945.2001.tb00392.x","article-title":"Update on the mechanisms of action of epileptic drugs","volume":"3","author":"Sills","year":"2001","journal-title":"Epileptic Disorders"},{"key":"10.1016\/j.seizure.2010.10.027_bib0115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nurt.2006.10.001","article-title":"Stiripentol","volume":"4","author":"Chiron","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.seizure.2010.10.027_bib0120","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1586\/14737175.6.3.397","article-title":"Refractory epilepsy: mechanisms and solutions","volume":"6","author":"Kwan","year":"2006","journal-title":"Expert Rev Neurotherapeutics"},{"key":"10.1016\/j.seizure.2010.10.027_bib0125","first-page":"68","article-title":"Key factors in the discovery and development of new antiepileptic drugs","volume":"9","author":"Bialer","year":"2010","journal-title":"Nature Rev"},{"key":"10.1016\/j.seizure.2010.10.027_bib0130","unstructured":"Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs, in press."},{"key":"10.1016\/j.seizure.2010.10.027_bib0135","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ncl.2009.06.007","article-title":"Selection of antiepileptic drugs in adults","volume":"27","author":"Stephen","year":"2009","journal-title":"Neurol Clin"},{"issue":"Suppl 4","key":"10.1016\/j.seizure.2010.10.027_bib0140","first-page":"S2","article-title":"Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy","volume":"60","author":"Kwan","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2010.10.027_bib0145","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","article-title":"Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy","volume":"68","author":"Brodie","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2010.10.027_bib0150","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine or topiramate for treatment of partial epilepsy: an unblended randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2010.10.027_bib0155","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2010.10.027_bib0160","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl Med"},{"issue":"Suppl. 10","key":"10.1016\/j.seizure.2010.10.027_bib0165","first-page":"31","article-title":"Response to antiepileptic drug therapy: winners and losers","volume":"46","author":"Brodie","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0170","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0175","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/01.wnl.0000286959.22040.6e","article-title":"Quantifying response to antiepileptic drugs: effect of past treatment history","volume":"70","author":"Schiller","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2010.10.027_bib0180","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1528-1167.2005.54904.x","article-title":"Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms","volume":"46","author":"Schmidt","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0185","unstructured":"Potschka H, Brodie MJ. Pharmacoresistance. In: Stefan H, Theodore WH editors. Handbook of clinical neurology, 3rd Series. Oxford, UK: Wiley-Blackwell, in press."},{"key":"10.1016\/j.seizure.2010.10.027_bib0190","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.0013-9580.2005.31904.x","article-title":"Potential role of drug transporters in the pathogenesis of medically intractable epilepsy","volume":"46","author":"Kwan","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0195","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1212\/01.wnl.0000187129.66353.13","article-title":"Serum antibodies in epilepsy and seizure-associated disorders","volume":"65","author":"Mcnight","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2010.10.027_bib0200","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archneurol.2009.5","article-title":"Diagnostic value of N-methyl-d-aspartate receptor antibodies in women with new-onset epilepsy","volume":"66","author":"Niehusmann","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.seizure.2010.10.027_bib0205","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1474-4422(09)70324-2","article-title":"Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen","volume":"9","author":"Lancaster","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2010.10.027_bib0210","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eplepsyres.2009.09.020","article-title":"Mitochondria, oxidative stress and temporal lobe epilepsy","volume":"88","author":"Waldbaum","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2010.10.027_bib0215","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1111\/j.1528-1167.2009.02087.x","article-title":"Excitatory effects of gap junction blockers on cerebral cortex seizure-like activity in rats and mice","volume":"50","author":"Voss","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0220","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1528-1157.1997.tb01142.x","article-title":"Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects","volume":"38","author":"Deckers","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0225","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/seiz.2000.0442","article-title":"Epilepsy after the first drug fails: substitution or add-on?","volume":"9","author":"Kwan","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2010.10.027_bib0230","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","article-title":"Lamotrigine substitution study: evidence for synergism with sodium valproate?","volume":"26","author":"Brodie","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2010.10.027_bib0235","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1528-1157.1999.tb00832.x","article-title":"The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction","volume":"40","author":"Pisani","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0240","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/archneur.1983.04050120047006","article-title":"Valproate\u2013ethosuximide combination therapy for refractory absence seizures","volume":"40","author":"Rowan","year":"1983","journal-title":"Arch Neurol"},{"key":"10.1016\/j.seizure.2010.10.027_bib0245","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/cpt1975186733","article-title":"The efficacy of carbamazepine combinations in epilepsy","volume":"18","author":"Cereghino","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.seizure.2010.10.027_bib0250","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/S0140-6736(94)93110-0","article-title":"Synergism with GABA-ergic drugs in refractory epilepsy","volume":"343","author":"Leach","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2010.10.027_bib0255","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(05)60613-7","article-title":"Lamotrigine and topiramate may be a useful combination","volume":"351","author":"Stephen","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2010.10.027_bib0260","series-title":"Epilepsy and other chronic convulsive diseases","author":"Gowers","year":"1881"},{"key":"10.1016\/j.seizure.2010.10.027_bib0265","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/ana.21166","article-title":"Likelihood of seizure remission in adult population with refractory epilepsy","volume":"62","author":"Callachan","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.seizure.2010.10.027_bib0270","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ana.21064","article-title":"Results of treatment changes in patients with apparently drug-resistance chronic epilepsy","volume":"62","author":"Luciano","year":"2007","journal-title":"Annal Neurol"},{"key":"10.1016\/j.seizure.2010.10.027_bib0275","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1528-1167.2009.02299.x","article-title":"Placebo-corrected efficacy of modern antiepileptic drugs and refractory epilepsy: systematic review and metaanalysis","volume":"51","author":"Beyenburg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0280","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1528-1167.2007.01136.x","article-title":"Seizure-free outcome in randomized add-on trials of new antiepileptic drugs","volume":"48","author":"Gazzola","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0285","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ana.21642","article-title":"Remission of epilepsy after two drug failures in children: a prospective study","volume":"65","author":"Berg","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.seizure.2010.10.027_bib0290","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1528-1167.2010.02546.x","article-title":"Course and outcome of childhood epilepsy: a 15 year follow-up of the Dutch Study of Epilepsy in Childhood","author":"Geerts","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0295","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1468-1331.2006.01215.x","article-title":"Diagnosing refractory epilepsy: response to sequential treatment schedules","volume":"13","author":"Mohanraj","year":"2006","journal-title":"Eur J Neurol"},{"issue":"Suppl. 11","key":"10.1016\/j.seizure.2010.10.027_bib0300","first-page":"411","article-title":"Improved outcomes in newly diagnosed epilepsy","volume":"50","author":"Brodie","year":"2009","journal-title":"Epilepsia"},{"issue":"Suppl. 3","key":"10.1016\/j.seizure.2010.10.027_bib0305","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1528-1167.2010.02602.x","article-title":"Therapeutic approaches to epileptogenesis\u2014Hope on the horizon","volume":"S1","author":"Pitk\u00e4nen","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2010.10.027_bib0310","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/archneurol.2009.10","article-title":"Emerging concepts in the pathogenesis of epilepsy and epileptogenesis","volume":"66","author":"Dichter","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.seizure.2010.10.027_bib0315","doi-asserted-by":"crossref","unstructured":"Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH et al. Revised terminology and concepts for organisation of the epilepsies: report of the Ilae commission and classification and terminology. Epilepsiadoi:10.1111\/j.1528-1167.2010.02522.x, in press.","DOI":"10.1111\/j.1528-1167.2010.02522.x"},{"key":"10.1016\/j.seizure.2010.10.027_bib0320","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S0140-6736(10)60598-3","article-title":"The personal genome\u2014the future of personalised medicine","volume":"375","author":"Samani","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2010.10.027_bib0325","unstructured":"Pope A. An essay on man; 1733\u20131734: 1.95."}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105913111000258X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105913111000258X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:38:51Z","timestamp":1761010731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105913111000258X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S105913111000258X"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2010.10.027","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiepileptic drug therapy the story so far","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2010.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}